NCT07107204

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

A Multicenter, Open-label, Single-arm Phase Ib/IIa Clinical Study to Evaluate the Safety and Efficacy of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 116 (estimated)
• Sponsor: Biotroy Therapeutics · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years . Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Conditions

• Relapsed or Refractory Hematologic Malignancies
• Leukemia
• Lymphoma
• Multiple Myeloma (MM)

Interventions

Type	Name	Description
DRUG	BT02	BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Timeline

• Start date: 2025-10-01
• Primary completion: 2028-01-01
• Completion: 2028-04-01
• First posted: 2025-08-06
• Last updated: 2025-09-17

Regulatory

• FDA-regulated drug study